Buttgereit, Frank http://orcid.org/0000-0003-2534-550X
Article History
Accepted: 6 January 2020
First Online: 19 February 2020
Competing interests
: F.B. declares that he has received consultancy fees, honoraria, travel expenses and grant support from Horizon Pharma, Mundipharma, Pfizer and Roche. The work of F.B. in the ongoing Rh-GIOP study (Glucocorticoid-induced osteoporosis in patients with chronic inflammatory rheumatic diseases or psoriasis; NCT02719314) is supported by joint funding from Amgen, BMS, Celgene, Generic Assays, GSK, Hexal, Horizon, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.